

Supplementary Materials: Applying Unconventional Secretion in *Ustilago maydis* for the Export of Functional Nanobodies

Marius Terfrüchte, Michèle Reindl, Silke Jankowski, Parveen Sarkari, Michael Feldbrügge and Kerstin Schipper

Table S1. Sequences of genes optimized according to the context-dependent dicodon usage of *Ustilago maydis* (*U. maydis*).

Encoded protein	Codon-optimized gene sequence (5'-3')	Company
anti-Gfp nanobody (α GfpNB) [1]	<p>ATGCCGACGTCCAGCTCGTCGAGTCGGGTGGTGCCTCG TCCAGCCCGGTGGCTCGCTGCGTCTCTCGTGCGCCCTCG GGCTCCCCGTCAACCGCTACTCGATGCGATGGTACCGTC AGGCGCCTGGCAAGGAGCGCGAGTGGTTCGCCGGCATGT CGTCGGCCGGTGACCGATCGTCGTACGAGGACTCGGTCAA GGTTCGCTTACCATCTCGCGCGACGACGCTCGCAACACC GTCTACCTCCAGATGAACTCGCTCAAGCCCGAGGACACCG CCGTCTACTACTGCAACGTCAACGTCCGGTTCGAGTACTG GGTTCAGGGCACCCAGGTCACCGTCTCGTCA</p> <p>ATGCCGCCCCATCACCACCATCACCACCATCACCACCAT CATGGATCGGGTGGTGGTCTGGTCCAGTCCGGTGGCTCGC TGCGTCTCTCGTGGTCTCGTCTCGGGCTCGGACATCTCGGGC ATCGCGATGGGCTGGTACCGTCAAGGCTCCCGGCAAGCGTC GCGAGATGGTCCCGACATCTTCTCGGGTGGTTCGACCGA CTACGCCGGCTCGGTCAAGGGTCTTACCATCTCGCGC GACAACGCCAAGAAGACCTCGTACCTCCAGATGAACAAC GTCAGCCCGAGGACACCGGTGTCTACTACTGCCGTCTCT ACGGTCCGGCGACTACTGGGGTCAGGGCACCCAGGTCA CCGTCTCGTCA</p>	GeneArt (Thermo Fisher)
anti-botulinum toxin A nanobody (α BoNTANB) [2] ¹	<p>ATGCCGCCCCATCACCACCATCACCACCATCACCACCAT CATGGATCGGGTGGTGGTCTGGTCCAGTCCGGTGGCTCGC TGCGTCTCTCGTGGTCTCGTCTCGGGCTCGGACATCTCGGGC ATCGCGATGGGCTGGTACCGTCAAGGCTCCCGGCAAGCGTC GCGAGATGGTCCCGACATCTTCTCGGGTGGTTCGACCGA CTACGCCGGCTCGGTCAAGGGTCTTACCATCTCGCGC GACAACGCCAAGAAGACCTCGTACCTCCAGATGAACAAC GTCAGCCCGAGGACACCGGTGTCTACTACTGCCGTCTCT ACGGTCCGGCGACTACTGGGGTCAGGGCACCCAGGTCA CCGTCTCGTCA</p>	Integrated DNA Technologies, Inc.

¹ The synthesized sequence includes a 10 \times Histidin tag (His tag; bold font) which was also codon-optimized for use in *U. maydis*. The actual start of the anti-botulinum toxin A nanobody (α BoNTANB) sequence is directly behind the His tag.




Figure S1. Expression and unconventional secretion of an anti-Gfp nanobody (α GfpNB) in *U. maydis*. The figure is a replicate of Figure panels 1B and 1C. The protein ladder has additionally been

included to clearly visualize the band sizes and a larger part of the Coomassie Brilliant Blue (CBB) stained membranes is provided.




Figure S2. Expression and immobilized metal ion affinity chromatography (IMAC) purification of His-tagged Gfp (Gfp^H) produced in *Escherichia coli*. Identical volumes of the fractions were subjected to SDS-PAGE with subsequent CBB staining. CE, cell extract; FT, flow through; W, wash steps; E, elution fractions. Subscripts indicate concentrations of imidazole. Gfp^H is indicated with an arrowhead.




Figure S3. Positive control for nanobody enzyme-linked immunosorbent assay (ELISA) using commercial Gfp-binding protein. Detection of purified Gfp-strep-tag control protein (Gfp^S ; IBA) in ELISA assays using indicated amounts of total cell extracts of strains AB33 (no nanobody) and AB33kex2Δ/αGfpNB-Cts1. As a positive control, detection was also performed using indicated amounts of commercial Gfp-binding protein (GfpBP, ChromoTek). Saturated signals were detected with 100 ng purified GfpBP and 10 μg *U. maydis* cell extracts containing αGfpNB-Cts1. Note that due to the presence of a C-terminal his-tag in GfpBP, the experimental setup has been changed and detection was performed with an antibody directed against the His tag (αHis).




Figure S4. Titration of Gfp^H to determine suitable loading for Gfp-trap experiments. Indicated amounts of purified Gfp^H were incubated with chitin resin. The experimental setup was identical to the actual nanotrap experiments (Figure 5) just lacking cell extracts. The figure shows Western blots using primary α Gfp and α HA antibodies. The membrane was stained with CBB after detection. Increasing the Gfp^H amount to 1.0 μ g leads to inefficient washing and hence, unspecific bands in the elution fraction (indicated by arrowheads). Hence, no more than 500 ng input protein should be used in Gfp-trap experiments. I, input; FT, flow through; O, elution; W, last wash step.




Figure S5. Quantification of α BoNTANB-Cts1 in *U. maydis* supernatants. (A) Representative Western blot of defined amounts of MultiTag[®] standard protein and trichloroacetic acid (TCA) precipitated supernatants of *U. maydis* AB33kex2 Δ / α BoNTANB-Cts1 harvested 9 h post inoculation; (B) Standard curve from densitometric analysis of the MultiTag[®] standard protein depicted in A; (C) Amounts of α BoNTANB-Cts1 in $\mu\text{g/L}$ calculated from Western blot results of 1 mL precipitated AB33kex2 Δ / α BoNTANB-Cts1 supernatant. The experiment has been performed as a biological duplicate.

References (Supplementary Material)

1. Rothbauer, U.; Zolghadr, K.; Tillib, S.; Nowak, D.; Schermelleh, L.; Gahl, A.; Backmann, N.; Conrath, K.; Muyldermans, S.; Cardoso, M.C.; et al. Targeting and tracing antigens in live cells with fluorescent nanobodies. *Nature Methods* **2006**, *3*, 887–889.
2. Mukherjee, J.; Tremblay, J.M.; Leysath, C.E.; Ofori, K.; Baldwin, K.; Feng, X.; Bedenice, D.; Webb, R.P.; Wright, P.M.; Smith, L.A.; et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. *PLoS ONE* **2012**, *7*, e29941.